A novel gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer

Molecular Pharmacology

Volumn 79, Issue 3, 2011, Pages 360-367

  So, Jae Young ^a   Lee, Hong Jin ^a,d   Smolarek, Amanda K ^a   Paul, Shiby ^a   Wang, Chung Xiou ^a   Maehr, Hubert ^a   Uskokovic, Milan ^a   Zheng, Xi ^a,e   Conney, Allan H ^a,e   Cai, Li ^b,e   Liu, Fang ^a,c,e   Suh, Nanjoo ^a,e  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d Chung Ang University   (South Korea)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA,25 DIHYDROXY 20 21(3 YDROXY 3 DEUTEROMETHYL 4,4,4 TRIDEUTEROBUTYL) 23 YNE 26,27 HEXAFLUORO CHOLECALCIFEROL; ANTINEOPLASTIC AGENT; BXL 0124; CALCIUM; MEMBRANE PROTEIN; MESSENGER RNA; OSTEOPONTIN; PROTEIN CD44; PROTEIN P53; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CALCIUM BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CALCITRIOL; CALCIUM; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 79951999082     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.068403     Document Type: Article

References (35)

1. Al-Hajj M, Becker MW, Wicha M, Weissman I, and Clarke MF (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43-47. (Pubitemid 38167476)
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, and Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. (Pubitemid 36418143)
3. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, et al. (2009) An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 11:R66.
4. Collins AT, Berry PA, Hyde C, Stower MJ, and Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951. (Pubitemid 41713363)
5. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106:13820-13825.
6. Deeb KK, Trump DL, and Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7:684-700. (Pubitemid 47327412)
7. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112:4793-4807.
8. Fillmore C and Kuperwasser C (2007) Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9:303.
9. Fillmore CM and Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10:R25.
10. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, et al. (2008) Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134:62-73. (Pubitemid 351905743)
11. Götte M and Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66:10233-10237. (Pubitemid 44799736)
12. Hellström E, Robèrt KH, Samuelsson J, Lindemalm C, Grimfors G, Kimby E, Oberg G, Winqvist I, Billström R, and Carneskog J (1990) Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol 45:255-261.
13. Hines SL, Jorn HK, Thompson KM, and Larson JM (2010) Breast cancer survivors and vitamin D: a review. Nutrition 26:255-262.
14. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, et al. (2008) Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13:394-406. (Pubitemid 351609443)
15. Khan SA, Cook AC, Kappil M, Günthert U, Chambers AF, Tuck AB, and Denhardt DT (2005) Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 22:663-673.
16. Lee HJ, Ju J, Paul S, So JY, DeCastro A, Smolarek A, Lee MJ, Yang CS, Newmark HL, and Suh N (2009) Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 15:4242-4249.
17. Lee HJ, Liu H, Goodman C, Ji Y, Maehr H, Uskokovic M, Notterman D, Reiss M, and Suh N (2006) Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 72:332-343. (Pubitemid 43975086)
18. Lee HJ, Paul S, Atalla N, Thomas PE, Lin XJ, Yang I, Buckley B, Lu G, Zheng X, Lou YR, et al. (2008) Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res (Phila) 1:476-484.
19. Lee HJ, So JY, DeCastro A, Smolarek A, Paul S, Maehr H, Uskokovic M, and Suh N (2010) Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol 121:408-412.
20. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, and Chen JY (2007) Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67:2089-2097.
21. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, and Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037.
22. Maehr H, Lee HJ, Perry B, Suh N, and Uskokovic MR.(2009) Calcitriol derivatives with two different side chains at C-20. V. Potent inhibitors of mammary carcinogenesis and inducers of leukemia differentiation. J Med Chem 52:5505-5519.
23. Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, Smadja-Joffe F, and Poupon MF (2009) CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 100:918-922.
24. Miller FR, Santner SJ, Tait L, and Dawson PJ.(2000) MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92:1185-1186.
25. Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, and Lopez JA (2008) Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 10:210.
26. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, and Ponta H (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16:3074-3086. (Pubitemid 35424194)
27. Paul S, Rimando AM, Lee HJ, Ji Y, Reddy BS, and Suh N (2009) Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res (Phila) 2:650-657.
28. Ponta H, Sherman L, and Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33-45. (Pubitemid 36077255)
29. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, and Ailles LE (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:973-978. (Pubitemid 46154721)
30. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, and Nakshatri H (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59.
31. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, et al. (2010) Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 70:2840-2851.
32. Visvader JE and Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768.
33. Worsham MJ, Pals G, Schouten JP, Miller F, Tiwari N, van Spaendonk R, and Wolman SR (2006) High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96:177-186.
34. Xu H, Posner GH, Stevenson M, and Campbell FC (2010) Apc(MIN) modulation of vitamin D secosteroid growth control. Carcinogenesis 31:1434-1441.
35. Yu WH, Woessner JF Jr, McNeish JD, and Stamenkovic I (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307-323. (Pubitemid 34111411)